Variation in Management of Immune Suppression after Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 10, 2011, Pages 1528-1536

  Pidala, Joseph ^a,c   Lee, Stephanie J ^b   Quinn, Gwen ^a,c   Jim, Heather ^a,c   Kim, Jongphil ^a,c   Anasetti, Claudio ^a,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Graft versus host disease; Immune suppression; Physician survey; Practice variation

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL COMPETENCE; DONOR; GRAFT RECIPIENT; HEALTH CARE DISPARITY; HEALTH CARE SURVEY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; TREATMENT WITHDRAWAL;

EVIDENCE-BASED MEDICINE; FEMALE; GRAFT VS HOST DISEASE; GUIDELINE ADHERENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; MALE; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 80052971173     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.03.006     Document Type: Article

References (21)

1. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
2. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
3. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
4. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
5. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
6. Chao N.J., Chen B.J. Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol 2006, 43:32-41.
7. Stewart B.L., Storer B., Storek J., et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004, 104:3501-3506.
8. Ruutu T., Volin L., Elonen E. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. Transplant Proc 1988, 20:491-493.
9. Lonnqvist B., Aschan J., Ljungman P., Ringden O. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease. Br J Haematol 1990, 74:547-548.
10. Kansu E., Gooley T., Flowers M.E., et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. Blood 2001, 98:3868-3870.
11. Mengarelli A., Iori A.P., Romano A., et al. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Haematologica 2003, 88:315-323.
12. Burroughs L., Mielcarek M., Leisenring W., et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006, 81:818-825.
13. Ruutu T., Niederwieser D., Gratwohl A., Apperley J.F. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997, 19:759-764.
14. Trifilio S., Verma A., Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004, 33:735-739.
15. Lee S.J., Vogelsang G., Gilman A., et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002, 8:32-39.
16. Hsu B., May R., Carrum G., Krance R., Przepiorka D. Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 2001, 28:945-950.
17. Lee S.J., Joffe S., Artz A.S., et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008, 26:2162-2170.
18. Lee S.J., Astigarraga C.C., Eapen M., et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1231-1238.
19. Thorpe C., Ryan B., McLean S.L., et al. How to obtain excellent response rates when surveying physicians. Fam Pract 2009, 26:65-68.
20. McCloskey S.A., Tao M.L., Rose C.M., Fink A., Amadeo A.M. National survey of perspectives of palliative radiation therapy: role, barriers, and needs. Cancer J 2007, 13:130-137.
21. Asch D.A., Jedrziewski M.K., Christakis N.A. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997, 50:1129-1136.